Patents by Inventor Raymond F. Schinazi

Raymond F. Schinazi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230201237
    Abstract: The present disclosure relates to solid dosage forms comprising anti-HCV compounds and methods of using such dosage forms to treat or prevent HCV infection. Direct-acting antiviral agents (DAAs) have a high cure rate, and favorable tolerability in persons infected with hepatitis C virus (HCV). However, shorter courses of therapy can improve adherence, affordability, and increase DAAs accessibility. The addition of an NS3 protease inhibitor to dual NS5A-NS5B (nucleoside) inhibitors enhances antiviral efficacy, and reduces treatment duration to 3 weeks (wks) in individuals with a rapid virologic response (RVR), defined as plasma HCV RNA<500, or <1,000, IU/mL by Day 2 of treatment.
    Type: Application
    Filed: February 17, 2023
    Publication date: June 29, 2023
    Inventor: Raymond F. Schinazi
  • Patent number: 11629125
    Abstract: The present invention is directed to compounds, compositions and methods for preventing, treating or curing Hepatitis B (HBV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment, prevention or eradication of HBV infection.
    Type: Grant
    Filed: August 20, 2020
    Date of Patent: April 18, 2023
    Assignee: Emory University
    Inventors: Raymond F. Schinazi, Sebastien Boucle, Franck Amblard, Ozkan Sari, Leda Bassit
  • Publication number: 20230056135
    Abstract: The present invention is directed to compounds, compositions and methods for preventing, treating or curing hepatitis B (HBV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment, prevention or eradication of HBV infection.
    Type: Application
    Filed: October 4, 2019
    Publication date: February 23, 2023
    Applicant: Emory University
    Inventors: Raymond F. Schinazi, Franck Amblard, Bryan Cox, Che Chen, Leda Bassit
  • Publication number: 20230000893
    Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing Zika virus. The compounds include pyrimidine and purine nucleosides and prodrugs thereof, including certain N4-hydroxycytidine nucleoside derivatives, sulfasalazine, and various entry inhibitors.
    Type: Application
    Filed: March 22, 2017
    Publication date: January 5, 2023
    Inventors: Raymond F. Schinazi, Franck Amblard, Bryan D. Cox, Leda Bassit, Longhu Zhou, Christina Gavegnano
  • Publication number: 20220313696
    Abstract: Compounds, compositions, and methods of treatment and prevention of HIV, including HIV-1 and HIV-2, Dengue, and Chikungunya infection are disclosed. The compounds are TREM-1 inhibitors. Combinations of these TREM-1 inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, JAK inhibitors, macrophage depleting agents, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV, Dengue, or Chikungunya virus in an infected patient.
    Type: Application
    Filed: May 25, 2021
    Publication date: October 6, 2022
    Inventors: Raymond F SCHINAZI, Christina GAVEGNANO
  • Publication number: 20220273753
    Abstract: Compounds, compositions and methods for preventing, treating or curing a coronavirus, picornavirus, and/or hepeviridae virus infection in human subjects or other animal hosts. Specific viruses that can be treated include enteroviruses. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1 (OC43), and SARS-CoV-2. In another embodiment, the methods are used to treat a patient co-infected with two or more of these viruses, or a combination of one or more of these viruses and norovirus.
    Type: Application
    Filed: December 7, 2021
    Publication date: September 1, 2022
    Inventors: Raymond F. Schinazi, Keivan Zandi, Franck Amblard
  • Publication number: 20220110939
    Abstract: Compounds, compositions, and methods of treatment and prevention of Hepacivirus, Pestivirus, Flavivirus or Alphavirus infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of Hepacivirus, Pestivirus, Flavivirus or Alphavirus in an infected patient.
    Type: Application
    Filed: June 29, 2021
    Publication date: April 14, 2022
    Inventors: Christina Gavegnano, Raymond F Schinazi
  • Publication number: 20220071957
    Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 16, 2021
    Publication date: March 10, 2022
    Inventors: Sandrine Vendeville, David Bernard Smith, Leonid Beigelman, Vladimir Serebryany, Raymond F. Schinazi, Franck Amblard, Leda Bassit
  • Publication number: 20220040185
    Abstract: Compounds, compositions, and methods of treatment and prevention of HIV, including HIV-1 and HIV-2, Dengue, and Chikungunya infection are disclosed. The compounds are TREM-1 inhibitors. Combinations of these TREM-1 inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, JAK inhibitors, macrophage depleting agents, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV, Dengue, or Chikungunya virus in an infected patient.
    Type: Application
    Filed: May 25, 2021
    Publication date: February 10, 2022
    Inventors: Raymond F SCHINAZI, Christina GAVEGNANO
  • Patent number: 11207370
    Abstract: Compounds, compositions and methods for preventing, treating or curing a coronavirus, picornavirus, and/or hepeviridae virus infection in human subjects or other animal hosts. Specific viruses that can be treated include enteroviruses. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1 (OC43), and SARS-CoV-2. In another embodiment, the methods are used to treat a patient co-infected with two or more of these viruses, or a combination of one or more of these viruses and norovirus.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: December 28, 2021
    Assignee: Emory University
    Inventors: Raymond F. Schinazi, Keivan Zandi, Franck Amblard
  • Publication number: 20210395300
    Abstract: The present invention is directed to compounds, compositions and methods for preventing, treating or curing Norovirus infection in human subjects or other animal hosts.
    Type: Application
    Filed: May 25, 2021
    Publication date: December 23, 2021
    Inventors: Raymond F. Schinazi, Franck Amblard, Ladislau Kovari, Peng Liu, Shaoman Zhou, Benjamin D. Kuiper, Bradley J. Keusch
  • Patent number: 11065254
    Abstract: Compounds, compositions, and methods of treatment and prevention of HIV infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV in an infected patient.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: July 20, 2021
    Assignees: The United States Government As Represented By The Department of Veterans Affairs, Emory University
    Inventors: Christina Gavegnano, Raymond F. Schinazi
  • Patent number: 11052090
    Abstract: Compounds, compositions, and methods of treatment and prevention of HIV, including HIV-1 and HIV-2, Dengue, and Chikungunya infection are disclosed. The compounds are TREM-1 inhibitors. Combinations of these TREM-1 inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, JAK inhibitors, macrophage depleting agents, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV, Dengue, or Chikungunya virus in an infected patient.
    Type: Grant
    Filed: February 12, 2020
    Date of Patent: July 6, 2021
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Raymond F. Schinazi, Christina Gavegnano
  • Patent number: 11045474
    Abstract: Compounds, compositions, and methods of treatment and prevention of HIV infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV in an infected patient.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: June 29, 2021
    Assignees: Emory University, The United States Government as Repersentative by the Department of Veterans Affairs
    Inventors: Christina Gavegnano, Raymond F. Schinazi
  • Patent number: 11021513
    Abstract: The present invention is directed to compounds, compositions and methods for preventing, treating or curing Norovirus infection in human subjects or other animal hosts.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: June 1, 2021
    Assignee: EMORY UNIVERSITY
    Inventors: Raymond F. Schinazi, Franck Amblard, Ladislau Kovari, Peng Liu, Shaoman Zhou, Benjamin D. Kuiper, Bradley J. Keusch
  • Publication number: 20210114981
    Abstract: The present invention is directed to compounds, compositions and methods for preventing, treating or curing Hepatitis B (HBV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment, prevention or eradication of HBV infection.
    Type: Application
    Filed: August 20, 2020
    Publication date: April 22, 2021
    Inventors: Raymond F. Schinazi, Sebastien Boucle, Franck Amblard, Ozkan Sari, Leda Bassit
  • Publication number: 20210060051
    Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing HIV and other viral infections, particularly where the virus is present in macrophages, microglia, and primary myeloid cells, and eliminating and/or treating infection in patients infected by these viruses.
    Type: Application
    Filed: December 27, 2018
    Publication date: March 4, 2021
    Inventors: Raymond F. Schinazi, Franck Amblard, Christina Gavegnano, Bryan Cox, Seema Mengshetti
  • Publication number: 20210052603
    Abstract: Compounds, compositions and methods for modulating retinoic acid receptor-like orphan receptors (ROR) and associated diseases. Methods for treatment or prophylaxis of metabolic disorders, liver disorders or diseases, including NASH, immune disorders, central nervous system disorders, or cancer are disclosed.
    Type: Application
    Filed: May 3, 2019
    Publication date: February 25, 2021
    Inventors: Raymond F. Schinazi, Bryan COX, Chofit CHAI, Hilla GILADI, Eithan GALUN, Franck AMBLARD
  • Publication number: 20210008150
    Abstract: Compounds, compositions and methods for preventing, treating or curing a coronavirus, picornavirus, and/or hepeviridae virus infection in human subjects or other animal hosts. Specific viruses that can be treated include enteroviruses. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1 (OC43), and SARS-CoV-2. In another embodiment, the methods are used to treat a patient co-infected with two or more of these viruses, or a combination of one or more of these viruses and norovirus.
    Type: Application
    Filed: June 5, 2020
    Publication date: January 14, 2021
    Inventors: Raymond F. Schinazi, Keivan Zandi, Franck Amblard
  • Publication number: 20200352948
    Abstract: Compounds, compositions, and methods of treatment and prevention of HTV infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV in an infected patient.
    Type: Application
    Filed: March 12, 2020
    Publication date: November 12, 2020
    Inventors: Christina Gavegnano, Raymond F. Schinazi